



COGNO
COOPERATIVE TRIALS GROUP
FOR NEURO-ONCOLOGY

POST SNO 2024 BRAIN CANCER UPDATE

Sponsored by Servier

Brought to you by the COGNO Outreach and Education Committee

Date: Tuesday, 10 December 2024

Time: 5.30-7pm

Format: Virtual - [please register here](#)

Aim: To review the latest and most significant treatment and research findings presented at the 2024 SNO Annual Meeting and explore how the new international data will impact patient care in Australia.

Program

Chair: Dr Sofia Mason

TIME	TOPIC	PRESENTER
5.30 – 5.35 pm	Welcome and Introduction	Dr Sofia Mason
Session 1: Translational science		
5.35 – 5.50 pm	Presentations: - Targeting glioma metabolism - Targeting malignant circuits in glioma - EcDNA and treatment resistance in glioblastoma	Dr Claire Storey
5.50 – 6.00 pm	Questions and panel discussion	Panel Members
Session 2: Clinical updates in low grade glioma		
6.00 – 6.15 pm	Presentations: - Update on IDH inhibition including the INDIGO trial, and outcomes after neoadjuvant ivosidenib and vorasidenib - Temozolomide with radiotherapy in grade 2 gliomas - Eflornathine plus lomustine in grade 3 astrocytoma	Dr Jim Whittle
6.15 – 6.25 pm	Questions and panel discussion	Panel Members
Session 3: Clinical updates in glioblastoma		
6.25 – 6.40 pm	Presentations: - Targeted therapies including TRK inhibition, paxalisib and ATM inhibition - Developments in immune therapies including CAR-T, vaccine therapies and neoadjuvant PDI	Dr Hao-Wen Sim
6.40 – 6.50 pm	Questions and panel discussion	Panel Members
6.50 – 7.00 pm	Closing remarks	Dr Sofia Mason
7.00 pm	Close	